FDA to Remove Warnings from Hormone Replacement Therapy Products
The U.S. Food and Drug Administration (FDA) has announced plans to eliminate “black box” warning labels from hormone replacement therapy (HRT) products aimed at easing menopause symptoms. Dr. Marty McCurry, the FDA Commissioner, stated that this decision is backed by years of research and clinical trials that do not substantiate earlier fears of increased mortality from breast cancer associated with the therapy.
At a press conference on Monday, Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. criticized the black box label, which is the most severe warning that can be mandated for prescription drugs, claiming it serves to “scare women and silence doctors.” He expressed that the warnings cited diseases and risks not supported by data, indicating that FDA officials acted out of fear rather than adhering to scientific evidence. “The outcome was disastrous,” Kennedy remarked.
McCurry pointed out that a significant 2002 study called the Women’s Health Initiative, which raised alarms about hormone therapy and breast cancer, had been “misrepresented” and generated unnecessary panic.
In an editorial released just hours before the announcement, McCurry described HRT—comprised of estrogen and progesterone (or just estrogen for women who have undergone a hysterectomy)—as a vital breakthrough for many women. He noted that while it alleviates immediate menopause symptoms like hot flashes and mood swings, the long-term benefits of starting treatment within a decade post-menopause may be undervalued, even by healthcare providers.
The FDA’s black box warnings, introduced in 2003, were based on misunderstood data and have discouraged many women from pursuing HRT.
McCurry also highlighted research from 1991 showing that HRT could cut fatal coronary incidents by around 50%, along with a 1996 study indicating that women utilizing estrogen therapy faced a 35% reduced risk of Alzheimer’s disease compared to those who did not.
Urologist Kelly Casperson remarked at the HHS event that eliminating the black box warning would help rectify decades of misleading advice. “This decision is not merely regulatory; it is revolutionary,” she stated.
